Looking Into Seres Therapeutics's Return On Capital Employed
Portfolio Pulse from Benzinga Insights
Seres Therapeutics (NASDAQ:MCRB) reported Q1 sales of $-522 thousand and a loss of $71.17 million, a 3.46% decrease from last quarter. The company posted a return on capital employed (ROCE) of 1.49%, suggesting effective capital allocation. However, Q1 earnings per share of $-0.57 did not meet analyst predictions of $-0.55.
May 24, 2023 | 2:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Seres Therapeutics reported a Q1 loss of $71.17M and a 1.49% ROCE, indicating effective capital allocation. However, Q1 EPS of $-0.57 missed analyst predictions.
Seres Therapeutics' Q1 results show a loss and a positive ROCE, suggesting effective capital allocation. However, the missed EPS prediction may offset any potential positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100